Utilizing Current Diagnostic Criteria and Treatment Algorithms for Managing Type 2 Diabetes Mellitus

References

• . Centers for Disease Control and Prevention. 2011 National Diabetes Fact Sheet. Atlanta, GA: CDC; 2011
   Google Scholar
• . Nathan DM, Buse JB, Davidson MB,; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193–203
   PubMed Web of Science ®Google Scholar
• . Huang ES, Basu A, O'Grady M, Capretta JC. Projecting the future diabetes population size and related costs for the U.S. Diabetes Care. 2009; 32(12):2225–2229
   PubMed Web of Science ®Google Scholar
• . Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005–2050. Diabetes Care. 2006;29(9):2114–2116
   PubMed Web of Science ®Google Scholar
• . Ogden CL, Carroll MD, McDowell MA, Flegal KM. Obesity among adults in the United States—no statistically significant change since 2003–2004. NCHS Data Brief. 2007(1):1–8
   Google Scholar
• . Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, Koplan JP. The spread of the obesity epidemic in the United States, 1991–1998. JAMA. 1999;282(16):1519–1522
   PubMed Web of Science ®Google Scholar
• . Lindgren CM, McCarthy MI. Mechanisms of disease: genetic insights into the etiology of type 2 diabetes and obesity. Nat Clin Pract Endocrinol Metab. 2008;4(3):156–163
   PubMedGoogle Scholar
• . Edelman S, Henry RR. Diagnosis and Management of Type 2 Diabetes. 8th ed. West Islip, NY: Professional Communications, Inc.; 2007
   Google Scholar
• . Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–2012
   PubMed Web of Science ®Google Scholar
• . Kahn SE, Haffner SM, Heise MA,; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427–2443
   PubMed Web of Science ®Google Scholar
• . U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44(11):1249–1258
   PubMed Web of Science ®Google Scholar
• . Peyrot M, Rubin RR, Lauritzen T, Snoek FJ, Matthews DR, Skovlund SE. Psychosocial problems and barriers to improved diabetes management: results of the Cross-National Diabetes Attitudes, Wishes and Needs (DAWN) Study. Diabet Med. 2005;22(10):1379–1385
   PubMed Web of Science ®Google Scholar
• . Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31(1):81–86
   PubMed Web of Science ®Google Scholar
• . Standards of medical care in diabetes—2010. Diabetes Care. 2010;33( suppl 1):S11–S61
   PubMed Web of Science ®Google Scholar
• . National Committee for Quality Assurance. The state of health care quality 2007. http://www.ncqa.org/Portals/0/Publications/Resource%20Library/SOHC/SOHC_07.pdf. Accessed April 16, 2010
   Google Scholar
• . Rodbard HW, Jellinger PS, Davidson JA,. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540–559
   PubMed Web of Science ®Google Scholar
• . AACE/ACE diabetes algorithm for glycemic control. http://www.aace.com/pub/pdf/GlycemicControlAlgorithmPPT.pdf. Accessed February 3, 2011
   Google Scholar
• . Rodbard HW, Blonde L, Braithwaite SS,; AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract. 2007;13( suppl 1):1–68
   PubMedGoogle Scholar
• . American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes. Endocr Pract. 2010;16(2):155–156
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2011;34( suppl 1):S62–S69
   PubMed Web of Science ®Google Scholar
• . Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31(8):1473–1478
   PubMed Web of Science ®Google Scholar
• . Jansen JP. Self-monitoring of glucose in type 2 diabetes mellitus: a Bayesian meta-analysis of direct and indirect comparisons. Curr Med Res Opin. 2006;22(4):671–681
   PubMed Web of Science ®Google Scholar
• . Sarol JN Jr, Nicodemus NA Jr, Tan KM, Grava MB. Self-monitoring of blood glucose as part of a multi-component therapy among non-insulin requiring type 2 diabetes patients: a meta-analysis (1966–2004). Curr Med Res Opin. 2005;21(2):173–184
   PubMed Web of Science ®Google Scholar
• . Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–885
   PubMed Web of Science ®Google Scholar
• . Woerle HJ, Neumann C, Zschau S,. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes: Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77(2):280–285
   PubMed Web of Science ®Google Scholar
• . Schernthaner G, Guerci B, Gallwitz B,. Impact of postprandial and fasting glucose concentrations on HbA1c in patients with type 2 diabetes. Diabetes Metab. 2010;36(5):389–394
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Hissa MN, Garber AJ,; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32(9):1649–1655
   PubMed Web of Science ®Google Scholar
• . Charbonnel B, Karasik A, Liu J, Wu M, Meininger G. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29(12):2638–2643
   PubMed Web of Science ®Google Scholar
• . Taskinen MR, Rosenstock J, Tamminen I,. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13(1):65–74
   PubMed Web of Science ®Google Scholar
• . DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28(5):1092–1100
   PubMed Web of Science ®Google Scholar
• . Nauck M, Frid A, Hermansen K,; LEAD-2 Study Group. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009;32(1):84–90
   PubMed Web of Science ®Google Scholar
• . Pratley RE. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med. 2008;10(7):171
   PubMedGoogle Scholar
• . Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194–206
   PubMed Web of Science ®Google Scholar
• . Onglyza (saxagliptin) [package insert]. Princeton, NJ/Wilmington, DE: Bristol-Myers Squibb/AstraZeneca Pharmaceuticals; 2011
   Google Scholar
• . Victoza (liraglutide [rDNA origin]) [package insert]. Princeton, NJ: Novo Nordisk, Inc; 2010
   Google Scholar
• . Januvia (sitagliptin) [package insert]. Whitehouse Station, NJ: Merck & Co Inc; 2011
   Google Scholar
• . Tradjenta (linagliptin) [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals Inc; 2011
   Google Scholar
• . Byetta (exenatide) [package insert]. San Diego, CA: Amylin Pharmaceuticals Inc; 2010
   Google Scholar